



409 12<sup>th</sup> Street, SW  
Suite 601  
Washington, DC 20024  
SMFM.org

**EXECUTIVE COMMITTEE**

President 2021-2022  
William Grobman, MD, MBA  
Chicago, IL

President-Elect 2021-2022  
Joanne Stone, MD, MS  
New York, NY

Secretary-Treasurer 2021-2022  
Anthony Sciscione, DO  
Wilmington, DE

Assistant Secretary-Treasurer 2021-2022  
Cynthia Gyamfi-Bannerman, MD, MSc  
New York, NY

Immediate Past President 2021-2022  
Judette Louis, MD, MPH  
Tampa, FL

**SMFM CEO**

Christina Wurster, MBA  
Washington, DC

**BOARD OF DIRECTORS**

John Allbert, MD  
Charlotte, NC

Brian Bost, MD  
Winston-Salem, NC

Allison Bryant Mantha, MD, MPH  
Boston, MA

Fadi Bsar, MD  
Springfield, MA

Helen Feltovich, MD  
Provo, UT

Brenna Hughes, MD, MSc  
Durham, NC

Vanita Jain, MD  
Newark, DE

Torri Metz, MD, MSCI  
Salt Lake City, UT

Christian Pettker, MD  
New Haven, CT

Amber Samuel, MD  
Spring, TX

Erika Werner, MD  
Providence, RI

Blair Wylie, MD  
Boston, MA

**EX-OFFICIO REPRESENTATIVES**

Thomas Lee, MD, MBA  
Portland, OR

Monica Longo, MD, PhD  
Bethesda, MD

Tani Malhotra, MD  
Cleveland, OH

Brian Mercer, MD  
Cleveland, OH

Shannon Son, MD  
Salt Lake City, UT

George Wendel, MD  
Dallas, TX

May 7, 2021

Dr. Janet Woodcock  
Food and Drug Administration  
10903 New Hampshire Ave  
Silver Spring, MD 20903-0002

Dear Dr. Woodcock,

On behalf of the Society for Maternal-Fetal Medicine (SMFM), we would like to thank you for your response and action to lift the Risk Evaluation and Mitigation Strategy (REMS) in-person dispensing requirement on Mifepristone for the remainder of the public health emergency. We applaud your efforts to allow individuals to access medication abortion care in a manner that is safe for both patients and healthcare personnel. Allowing the dispensing of Mifepristone through the mail will greatly benefit patients who need accessible abortion care.

These challenging times have both highlighted and exacerbated the inequality of access to reproductive health care services, including medication abortion. SMFM is committed to expanding access to abortion services and ensuring that individuals are receiving high-quality and equitable reproductive health care, including abortion. It is imperative that all individuals have full autonomy over their bodies and that rules and regulations on reproductive health be governed by scientific evidence and not political or ideological values.

SMFM appreciates your leadership in dismantling barriers to Mifepristone access for the remainder of the public health emergency. It is our hope that this progress will continue, and you will permanently remove the REMS on Mifepristone past the public health emergency. Again, thank you and SMFM and our members stand ready to assist in any way we can to improve access to medication abortion care.

Kind regards,

William Grobman, MD, MBA  
President

Christina J. Wurster, MBA, CAE  
Chief Executive Officer

